Mood improvement and depression relief
Venetron® demonstrates clinically significant mood improvement effects through its SSRI-like serotonin reuptake inhibiting mechanism — increasing synaptic serotonin availability in mood-regulating brain circuits. Multiple clinical studies confirm significant reductions in depression scores (BDI, Hamilton Depression Rating Scale) and improved mood vs. placebo, with effects comparable to low-dose pharmaceutical antidepressants in mild-to-moderate depression.
Anxiety relief and stress management
Hyperoside and isoquercitrin from Venetron® modulate GABA-A receptors (anxiolytic mechanism) and 5-HT1A serotonin autoreceptors — reducing hyperactivation of the stress response system. Clinical studies confirm significant reductions in anxiety scores and improved stress resilience with Venetron® supplementation vs. placebo.
Sleep quality improvement
By reducing the serotonergic and noradrenergic arousal that impairs sleep onset, and through mild GABA-A modulation that reduces neurological hyperactivation, Venetron® improves sleep quality, reduces sleep latency, and improves sleep satisfaction. The serotonin-melatonin biosynthetic pathway (serotonin is melatonin's precursor) provides an additional mechanism for Venetron®'s sleep benefits.
Serotonin transporter inhibition and 5-HT1A modulation
Hyperoside and isoquercitrin from Venetron® inhibit the serotonin transporter (SERT) — the same mechanism as pharmaceutical SSRIs (fluoxetine, sertraline) — increasing synaptic serotonin concentrations in prefrontal cortex and limbic circuits governing mood and emotional regulation. Venetron® flavonoids simultaneously modulate 5-HT1A autoreceptors, normalizing the serotonergic tone disrupted in depression and anxiety. The combined SERT inhibition + 5-HT1A modulation produces the antidepressant and anxiolytic profile observed clinically.
Randomized, double-blind, placebo-controlled trial of Venetron® (50 mg/day) effects on mood, depression, and anxiety scores.
Adults with mild-to-moderate depression or anxiety. Clinical assessment using validated mood scales.
Venetron® produced significant improvements in depression scores (BDI, Hamilton), anxiety measures, and sleep quality vs. placebo. SSRI-like mood improvement without pharmaceutical side effects. Onset within 1–2 weeks. Well-tolerated in clinical studies.